

University of Groningen

## Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma

Reijers, Sophie J.M.; Husson, Olga; Soomers, Vicky L.M.N.; Been, Lukas B.; Bonenkamp, Johannes J.; van de Sande, Michiel A.J.; Verhoef, Cornelis; van der Graaf, Winette T.A.; van Houdt, Winan J.

*Published in:*  
European Journal of Surgical Oncology

*DOI:*  
[10.1016/j.ejso.2021.08.007](https://doi.org/10.1016/j.ejso.2021.08.007)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2022

[Link to publication in University of Groningen/UMCG research database](#)

### *Citation for published version (APA):*

Reijers, S. J. M., Husson, O., Soomers, V. L. M. N., Been, L. B., Bonenkamp, J. J., van de Sande, M. A. J., Verhoef, C., van der Graaf, W. T. A., & van Houdt, W. J. (2022). Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort? *European Journal of Surgical Oncology*, 48(3), 500-507. <https://doi.org/10.1016/j.ejso.2021.08.007>

### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.


### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Contents lists available at ScienceDirect

## European Journal of Surgical Oncology

journal homepage: [www.ejso.com](http://www.ejso.com)

# Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?



Sophie J.M. Reijers<sup>a</sup>, Olga Husson<sup>b, c, d</sup>, Vicky L.M.N. Soomers<sup>e</sup>, Lukas B. Been<sup>f</sup>, Johannes J. Bonenkamp<sup>g</sup>, Michiel A.J. van de Sande<sup>h</sup>, Cornelis Verhoef<sup>i</sup>, Winette T.A. van der Graaf<sup>b, j</sup>, Winan J. van Houdt<sup>a, \*</sup>

<sup>a</sup> Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands

<sup>b</sup> Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands

<sup>c</sup> Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands

<sup>d</sup> Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom

<sup>e</sup> Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands

<sup>f</sup> Department of Surgical Oncology, University Medical Center Groningen, Groningen, the Netherlands

<sup>g</sup> Department of Surgical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands

<sup>h</sup> Department of Orthopaedic Oncology, Leiden University Medical Center, Leiden, the Netherlands

<sup>i</sup> Department of Surgical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands

<sup>j</sup> Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands

## ARTICLE INFO

## Article history:

Received 20 April 2021

Received in revised form

12 July 2021

Accepted 6 August 2021

Available online 8 August 2021

## Keywords:

Quality of life

Soft tissue sarcoma

Isolated limb perfusion

Amputation

## ABSTRACT

**Introduction:** The aim of this study was to compare long-term patient reported outcomes (PROs) in patients with locally advanced extremity soft tissue sarcoma (eSTS) after isolated limb perfusion followed by resection (IR), compared to extended resection (ER), primary amputation (A) or secondary amputation after IR (IR-A).

**Methods:** Patients were selected from the respondents of a multi-institutional cross-sectional cohort survivorship study (SURVSARC) conducted among sarcoma survivors registered in the Netherlands Cancer Registry (NCR), 2–10 years after diagnosis. Used PROs were the EORTC QLQ-C30, the Cancer worry scale (CWS), the Hospital Anxiety and Depression Scale (HADS), and the Toronto Extremity Salvage Score (TESS).

**Results:** We identified 97 eSTS survivors: IR = 20, ER = 49, A = 20, IR-A = 8. While there were no differences in PROs between IR and ER, results showed better functioning and functionality in both groups versus the amputation groups. The amputation groups scored significantly lower on physical functioning (A = 62.7, IR-A = 65.7 versus IR = 78.0, ER = 82.7,  $p = 0.001$ ) and role functioning (A = 67.5, IR-A = 52.8 versus IR = 79.2, ER = 80.6,  $p = 0.039$ ), both EORTC QLQ-C30 scales. Also for the TESS, the scores were significantly lower for the amputation groups compared to the limb sparing groups (upper extremity  $p = 0.007$  with A = 68.9, IR-A = 71.6 versus IR = 93.3, ER = 91.1; lower extremity  $p < 0.001$  with A = 72.2, IR-A = 50.9 versus IR = 84.5 and ER = 85.5). There were no significant differences between the groups on cancer worry, anxiety and depression.

**Conclusion:** HRQoL in eSTS survivors treated with IR or ER is equal; for maintenance of physical functioning and functionality IR and ER outperform an amputation.

© 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

## 1. Introduction

Limb salvage surgery (LSS) is the cornerstone of treatment for extremity soft tissue sarcoma (eSTS) [1]. Wide local excision is often

\* Corresponding author. Netherlands Cancer Institute Sarcoma Unit, Department of Surgical Oncology, Plesmanlaan 121, Amsterdam, 1066 CX, the Netherlands.

E-mail address: [w.v.houdt@nki.nl](mailto:w.v.houdt@nki.nl) (W.J. van Houdt).

combined with (neo)adjuvant radiotherapy, or to a lesser extent with (neo)adjuvant chemotherapy in high risk sarcomas. For locally advanced primary, as well as recurrent eSTS, an extended resection is often indicated, and some tumors may need amputation for adequate local disease management [2,3]. These extended resections may comprise debulking of a whole extremity compartment, occasionally including resection of vasculature and nerves.

While radiotherapy does not lead to tumor size reduction in most cases, isolated limb perfusion (ILP) frequently downsizes locally advanced tumors, potentially allowing for LSS [4–7]. An ILP involves isolation of the limb vascular system from the systemic circulation, allowing administration of dose intensified cytotoxic therapies (mostly TNF $\alpha$  and Melphalan) with acceptable toxicity [8]. Using this strategy, limb salvage rates (LSR) of 62–96% have been reported, with overall response rates (ORR) ranging from 61 to 90% and complete response rates (CRR) of 17–59% [4–7,9–16].

Although the limb salvation rate is relatively high in eSTS, the response to ILP is not always sufficient to prevent amputation, resulting in a secondary amputation. Also, in a small percentage of patients, toxicity of ILP may lead to a treatment induced amputation (Wieberdink grade V) [17]. Since amputations are major procedures with potentially profound implications such as increased degree of disability and post amputation pain (PAP), they are usually only performed as a last resort when no other options are available, based on a balance between expectations of functional and oncological outcome. No survival differences have been demonstrated between the different local surgical treatments, which can be explained by the fact that survival is mainly determined by distant metastases [3,18,19].

While ILP is usually considered a safe and well tolerated procedure, given the (very low) risk of major complications, health-related quality of life (HRQoL) should be taken into account when considering ILP. Although there is ample literature discussing ILP and limb salvation rate, data discussing long-term HRQoL after ILP compared to extended resections or amputation in eSTS is scarce. Therefore, the aim of this study is to analyze long term HRQoL (including functioning and symptoms) and other PROs (such as limb functionality, cancer worry, anxiety and depression) after ILP followed by resection, compared to extended resection or amputation after ILP for locally advanced eSTS.

## 2. Methods

Patients were selected from the database of a multi-institutional cross-sectional cohort study (SURVSARC), conducted among all sarcoma survivors who were registered in the Netherlands Cancer Registry (NCR) and have been diagnosed and treated between 1-1-2008 and 31-12-2016 within one of the six participating Dutch sarcoma centers (Netherlands Cancer Institute [Amsterdam], Erasmus Medical Centre [Rotterdam], Leiden University Medical Centre, Radboud University Medical Centre [Nijmegen], University Medical Centre Groningen, Maastricht University Medical Centre). Ethical approval was granted by the medical ethical committee of the Radboud University Medical Centre (2017–3944), and the study was registered in the Dutch Trial Registry (NTR-7253).

The study assessed subjective PRO's like HRQoL and illness related symptoms from sarcoma survivors on one single time point 2–10 years after diagnosis, by means of a self-administered questionnaire composed of several validated questionnaires [20]. From these questionnaires, we selected questions regarding surgery related outcomes and the following HRQoL questionnaires: the 30-item core European Organization for the Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30), the Cancer worry scale (CWS), the Hospital Anxiety and Depression Scale (HADS) and the Toronto Extremity Salvage Score (TESS). The

questionnaire also covered patient reported treatment details, because the NCR contains treatment data of the primary tumor (registered 6–9 months after diagnosis) and since 2016 treatment data on recurrent disease within 3 years after primary diagnosis. From the NCR socio-demographic and clinical characteristics (such as gender, age, tumor subtype, tumor grade, stage at diagnosis, tumor-location, primary treatment, and time since diagnosis) were extracted.

The general response rate of the study was 58%: 1099 patients were included [20]. Of these respondents, 576 were extremity sarcoma survivors. After excluding the bone sarcoma patients (N = 136), we selected eSTS survivors based on some specific patient reported surgical treatments (IR, ER, A and IR-A), see Fig. 1. To identify these patients with a presumably extended resection (ER group) from the NCR, which lacks specific tumor and surgical specifications, we defined an extended resection as all patients that received surgery for stage III STS, meaning tumors of at least 5 cm and at least grade 2 according to FFCSSG classification [21]. Patients without resection (n = 8), tumor stage unknown (n = 42) and resection for < stage III disease (low grade or  $\leq$ 5 cm tumors, n = 293) were categorized as 'other', see Fig. 1. Details regarding amputation levels other than upper or lower extremity are unknown.

### 2.1. EORTC health related quality-of-Life Questionnaire (QLQ-C30)

The EORTC QLQ-C30 is one of the most widely used cancer HRQoL questionnaires. It consists of 30 items assessing HRQoL across five functioning scales (physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning), three multi-item symptom scales (fatigue, pain, nausea and vomiting), six single-item symptom scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial problems) and global quality-of-life (QoL) [22]. Scores range from 0 to 100 after transformation by linear transformation following the QLQ-C30 scoring manual [23]. A higher score on the functioning scales and on global QoL represent a better level of functioning and global QoL, and a higher score on the symptom scales means a higher level of symptoms.

### 2.2. Cancer worry scale (CWS)

Cancer worry scale (CWS) assesses the concerns about the recurrence of cancer and the impact of these concerns on daily functioning among individuals at risk for (hereditary) cancer [24].


The Dutch version of the CWS has two extra items compared to the original questionnaire, which address focus on family members and future surgery [25]. Higher (>14) scores indicate more frequent worries about cancer.

### 2.3. Hospital Anxiety and Depression Scale (HADS)

The Hospital Anxiety and Depression Scale (HADS) has two sub-scales to indicate the levels of anxiety and depression during the last week [26]. Higher (>8) scores indicate more anxiety, depressive symptoms, and psychological distress.

### 2.4. Toronto Extremity Salvage Score (TESS)

While the EORTC QLQ-C30 is a generic cancer HRQoL questionnaire which also briefly addresses physical functionality, the Toronto Extremity Salvage Score (TESS) is a specific validated questionnaire that assesses functional outcomes in patients with musculoskeletal tumors of the extremity [27]. Separate questionnaires exist for both the upper (29 questions) and lower limb (30



**Fig. 1.** Patient flow

\*No resection (n = 8), stage unknown (n = 42) and resection for < stage III disease (low grade or ≤5 cm tumors, n = 293).

questions), with the questions being specifically tailored to the function of the extremity. The raw score is converted to a total score ranging from 0 to 100 (percentage), with higher scores indicating less functional limitations.

### 2.5. Statistical analysis

All analyses were performed in IBM SPSS 25.0 for Windows (version 25) with a significance level of  $\alpha = 0.05$ . Patient characteristics, disease related data and operation effects were compared between the 4 groups with the Kruskal Wallis tests in case of numerical variables (without normal distribution) and Chi-Square tests in case of categorical variables. One-way ANOVA tests (to allow for post-hoc comparisons) were used to compare all the HRQoL scores (EORTC QLQ-C30, CWS, HADS and TESS) and subscales were compared using the Chi-Square test. For post-hoc analyses we used the Bonferroni test of which we have not corrected the significance level, given the small group sizes and the exploratory nature of this secondary analysis. For the EORTC QLQ-C30, clinical relevance of differences between groups are defined by Cocks et al. and were used to compare the different treatment groups [28].

## 3. Results

We selected a total of 97 survivors from the database who met our selection criteria: 20 survivors for the ILP followed by resection (IR) group (78 months (range 43–134) since diagnosis), 49 survivors for the extended resection (ER) group (52 months (range 23–133) since diagnosis), 20 survivors for the amputation (A) group (57 months (range 25–108) since diagnosis) and 8 survivors for the secondary amputation after IR (IR-A) group (96 months (range 25–126) since diagnosis), see Fig. 1. Patient and tumor related characteristics of the survivors can be found in Table 1. Most characteristics showed no differences between the groups, except for the application of radiotherapy, which was significantly less administered in the A group ( $p < 0.001$ ), wherein the ER group almost all had radiotherapy (90%). Time from diagnosis to study was significantly longer in the ILP groups ( $p = 0.004$ ) with a median overall follow-up time for the whole group of 60 months (range 23–134).

### 3.1. HRQoL

Most functioning scales showed no significant differences between the groups, except for the physical functioning (PF) scale and

the role functioning (RF) scale, where the scores for the LSS groups (IR and ER) were higher when compared to the amputation groups (A and IR-A), see Table 2 and Fig. 2. Clinical relevance of differences in EORTC QLQ-C30 scores are defined by Cocks et al. [28]. For PF, the mean scores in the IR and ER group (LSS) were respectively 78.0 (SD 18.2) and 82.7 (SD 16.5), compared to 62.7 (SD 23.4) in the A group and 65.7 (SD 20.9) in the IR-A group ( $p = 0.001$ ). Post Hoc test showed a specific significant difference between the ER and the A group ( $p = 0.001$ ), but the difference between the LSS groups and the IR-A group was not statistically significant. For RF, the mean scores for the groups IR and ER were respectively 79.2 (SD 24.1) and 80.6 (SD 23.7), compared to 67.5 (SD 31.3) for the A group and 52.8 (SD 30.6) for the IR-A group ( $p = 0.039$ ).

The only significant difference on the symptoms scales and/or items was for 'nausea and vomiting' with mean scores of 5.8 (SD 9.8) for IR, 1.0 (SD 4.0) for ER, 4.2 (SD 9.2) for A and 0 (SD 0) for IR-A ( $p = 0.033$ ). In addition, 'fatigue' showed a non-significant difference of 14.6 (between 29.4 for the IR group and 14.8 for the IR-A group), which accounts for a difference with 'medium' clinical relevance [28]. No differences were seen in the groups between radiotherapy and non-radiotherapy patients.

### 3.2. Cancer worry scale (CWS) and Hospital Anxiety and Depression Scale (HADS) outcome

There were no statistically significant differences on the CWS ( $p = 0.828$ ) between the four groups and all groups showed a score around the cut-off point (score of 13/14) which was not statistically significant different between the groups ( $p = 0.962$ ), as seen in Table 3.

For both the HADS subscales (anxiety and depression subscale), the majority of the scores categorize as low scores ( $\leq 7$ ). For the anxiety subscale this was 85% (IR), 76% (ER), 79% (A) and 100% (IR-A). For the depression subscale this was respectively 80%, 88%, 68% and 86%. Both subscales showed no statistically significant differences (respectively  $p = 0.851$  and  $p = 0.494$ ).

### 3.3. Toronto Extremity Salvage Score (TESS) outcome

The mean TESS scores showed almost no differences between IR and ER. However, the TESS scores were significant higher in the LSS groups than the amputation groups, for both the upper extremity ( $p = 0.007$ ) and lower extremity patients ( $p < 0.001$ ). For the TESS upper extremity, a post hoc test showed a statistically significant difference of  $p = 0.022$  between the ER group and the A group. For the TESS lower extremity, a post hoc test showed a statistically

**Table 1**  
Patient, tumor and treatment characteristics.

Characteristic	Limb salvage surgery				Amputation				p
	ILP + resection (IR) (n = 20)		Extended resection (ER) (n = 49)		Amputation (A) (n = 20)		ILP + amputation (IR-A) (n = 8)		
	n	(%)	n	(%)	n	(%)	n	(%)	
Gender									0.896
Male	14	(70)	31	(63)	13	(65)	6	(75)	
Female	6	(30)	18	(37)	7	(35)	2	(25)	
Localization tumor									0.287
Upper extremity	4	(20)	10	(20)	6	(30)	4	(50)	
Lower extremity	16	(80)	39	(80)	14	(70)	4	(50)	
Histologic subtypes									n.a.
Liposarcoma (LPS)									
Myxoid liposarcoma (MLS)	2	(10)	3	(6)	2	(10)	0	–	
Dedifferentiated liposarcoma (DDLPS)	1	(5)	3	(6)	1	(5)	0	–	
Myxofibrosarcoma (MFS)	3	(15)	19	(39)	5	(25)	3	(38)	
Leiomyosarcoma (LMS)	4	(20)	3	(6)	0	–	1	(13)	
Rhabdomyosarcoma (RMS)	1	(5)	1	(2)	1	(5)	0	–	
Synovial sarcoma (SS)	2	(10)	0	–	5	(25)	1	(13)	
Angiosarcoma (AS)	1	(5)	0	–	2	(10)	0	–	
Undifferentiated pleomorphic sarcoma (UPS)	3	(15)	4	(8)	0	–	0	–	
Epithelioid sarcoma (ES)	1	(5)	0	–	0	–	2	(25)	
Other STS	2	(10)	16	(33)	4	(20)	1	(13)	
Tumor differentiation									n.a.
Well differentiated	1	(5)	0	–	0	–	0	–	
Moderately differentiated	4	(20)	0	–	2	(10)	1	(13)	
Poorly differentiated/undifferentiated	8	(40)	49	(100)	8	(40)	3	(38)	
Unknown	7	(35)	0	–	10	(50)	4	(50)	
Tumor grade									n.a.
Low grade (grade 1)	7	(35)	0	–	2	(10)	2	(25)	
High grade (grade 2 or 3)	12	(60)	49	(100)	15	(75)	6	(75)	
Unknown	1	(5)	0	–	3	(15)	0	–	
Comorbidity									0.631
None	7	(35)	16	(33)	7	(35)	1	(13)	
One	7	(35)	12	(24)	8	(40)	3	(38)	
Two or more	6	(30)	21	(43)	5	(25)	4	(50)	
Local treatment									<0.001
Only surgery	4	(20)	5	(10)	12	(60)	3	(38)	
Surgery + radiotherapy	16	(80)	44	(90)	8	(40)	5	(62)	
Currently under treatment	3	(15)	9	(18)	5	(25)	1	(13)	0.875
Age at time of study (years) <sup>a</sup>	69	(24–92)	69	(37–88)	68	(30–82)	66	(46–82)	0.955
Age at time of diagnosis (years) <sup>a</sup>	63	(18–86)	63	(32–84)	64	(26–75)	55	(36–79)	0.819
Time since diagnosis to study (months) <sup>a</sup>	78	(43–134)	52	(23–133)	57	(25–108)	96	(25–126)	0.006

<sup>a</sup> Specifications are median (range).

significant difference between the both the LSS groups and the IR-A group, with  $p = 0.002$  for the IR group and  $p = 0.001$  for the ER group. In the IR-A group, the lower extremity results were worse than the upper extremity scores (difference of 20.69 points), which is also seen to a lesser extent in the LSS groups. No differences were observed in the groups between patients that received radiotherapy and patients that did not receive radiotherapy.

### 3.4. Late effects of surgery

In both the ER and the IR group, 55% evaluated their scar as ugly, in contrast to 30% in the A group and 12% in the IR-A treatment group, which was statistically significant different ( $p = 0.001$ ). Multiple survivors reported inconvenience caused by their scar, as shown in Table 4. Wound issues were not statistically different between the groups. From the survivors who were treated by means of an amputation, 11 survivors (55%) had post amputation pain (PAP) in the A group and 5 survivors (62.5%) in the IR-A treatment group.

## 4. Discussion

In this study, we showed that physical functioning and functionality after limb salvage by ILP was significantly better than after

amputation for locally advanced eSTS, while physical functioning and functionality after ILP and extended resections did not differ. No differences were found on other HRQoL domains. These results suggest that an ILP for patients who otherwise would undergo an amputation or highly morbid surgery is justified and lead to better HRQoL, while amputations in patients with eSTS lead to decreased HRQoL without survival benefit. To our knowledge, this is the first HRQoL-focused study comparing ILP to both amputations and larger resections.

Our results showed nearly the same statistically significant differences as Thijssens et al., who compared ILP ( $n = 30$ ) and ILP + amputation ( $n = 9$ ) with a reference group ( $n = 1063$ , a random population sample without sarcoma) [29]. Most patients in their study received adjuvant radiotherapy as well. The study showed lower physical functioning and role limitations for the ILP patients, as measured by the RAND-36 [29], but patients who received secondary amputation (after ILP,  $n = 9$ ) had worse physical functioning, social functioning and role limitations in comparison with the ILP patients, which is in line with our results as well. However, Podleska et al. [30] found no difference in HRQoL (EORTC QLQ-C30) and physical function (SMFA) between a group of STS patients undergoing ILP ( $n = 27$ ), when compared to the results of amputated osteosarcoma patients from Zahlten-Hinguranage et al. [31] ( $n = 22$ ) and to EORTC reference values for 'general population'



**Table 2**  
EORTC QLQ-C30.

Scale/item	Limb salvage surgery			Amputation			Post hoc analysis (Bonferroni)			Clinical relevance [28] <sup>b</sup>						
	ILP + resection (IR) (n = 20)			Extended resection (ER) (n = 48)			Amputation (A) (n = 20)				p					
	mean	SD	n	mean	SD	n	mean	SD	n							
Global health status/QoL (QoL)	82.9	13.6	20	75.3	18.5	49	77.5	16.7	20	72.6	17.8	7	0.354	n/a	Medium	
Functional scales																
Physical functioning (PF)	78.0	18.2	20	82.7	16.5	49	62.7	23.4	20	65.7	20.9	7	0.001	0.001 <sup>a</sup>	Medium	
Role functioning (RF)	79.2	24.1	20	80.6	23.7	48	67.5	31.3	20	52.8	30.6	6	0.039	0.092	Medium	
Emotional functioning (EF)	80.0	25.4	20	89.1	17.4	49	89.2	19.5	20	86.1	17.2	6	0.351	n/a	Trivial	
Cognitive functioning (CF)	82.5	19.8	20	88.4	20.8	49	90.8	19.8	20	86.1	6.8	6	0.581	n/a	Small	
Social functioning (SF)	87.5	17.0	20	85.7	24.1	49	85.0	19.4	20	80.6	26.7	6	0.923	n/a	Small	
Symptom scales and/or items																
Fatigue (FA)	29.4	23.7	20	22.2	20.9	48	21.1	18.0	20	14.8	9.1	6	0.370	n/a	Medium	
Nausea and vomiting (NV)	5.8	9.8	20	1.0	4.0	49	4.2	9.2	20	0	0	6	0.033	n/a	Small	
Pain (PA)	20.8	22.9	20	16.3	22.9	49	15.0	20.9	20	13.9	16.4	6	0.821	n/a	Small	
Dyspnoea (DY)	16.7	27.6	20	11.1	19.8	48	8.3	18.3	20	16.7	27.9	6	0.613	n/a	Small	
Insomnia (SI)	25.0	35.7	20	15.6	22.7	49	20.0	29.4	20	22.2	40.4	6	0.643	n/a	Small	
Appetite loss (AP)	5.0	16.3	20	3.5	15.7	48	5.0	12.2	20	0	0	6	0.877	n/a	Trivial	
Constipation (CO)	5.0	12.2	20	4.1	13.0	49	8.3	18.3	20	5.6	13.6	6	0.731	n/a	Trivial	
Diarrhea (DI)	8.3	18.3	20	6.8	16.6	49	6.7	17.4	20	0	0	6	0.764	n/a	Medium	
Financial difficulties (FI)	11.7	27.1	20	8.2	24.1	49	16.7	25.4	20	11.1	27.2	6	0.650	n/a	Small	

<sup>a</sup> Between the extended resection group and the amputation group.

<sup>b</sup> Large clinical difference: unequivocal clinical relevance. Medium clinical relevance: likely to be clinically relevant but to a lesser extent. Small clinical relevance: subtle but nevertheless clinically relevant. Trivial clinical relevance: unlikely to have any clinical relevance [28].

and 'all cancer patients'. However, this study compares different groups from different studies with different diseases, making their comparison not entirely valid.

The well-cited, but historical, randomized controlled trial of Sugarbaker et al., who randomized eSTS patients between extended resection combined with adjuvant radiotherapy and chemotherapy (total n = 27, n = 12 for HRQoL measurements) versus primary amputation plus chemotherapy (total n = 16, n = 9 for HRQoL measurements), showed comparable HRQoL outcomes between the groups [19,32]. Other studies regarding LSS (ILP not included) showed that HRQoL after an extended resection initially decreases in the first months after surgery when compared to baseline, but improves significantly in the first year [33]. Also, 'restriction in participation of life roles and situations' has the greatest effect on HRQoL when it comes to functional disability after LSS [34] and the expectation of the patient with respect to their recovery seems to influence functional outcome after limb sparing surgery [35]. Johansen and David also showed better functional outcomes for ER compared to amputation [36,37].

Amputation level for locally advanced eSTS was shown to correlate with functionality; higher amputation levels resulted in lower TESS scores (p < 0.001) [38]. Unfortunately these data is lacking in our study as well as the other mentioned studies above.

In our study, physical limitations were overt in both amputation groups as measured by the statistically significant lower scores on the EORTC QLQ-C30 PF scale. The EORTC QLQ-C30 RF scale was also significantly lower in the amputation groups, which is not surprising as this is very much related to PF, because it assesses the ability of a patient to perform daily activities, work and/or leisure-time activities, which can be affected when missing a (part of a) limb. Statistically significant lower TESS scores for both amputation groups confirms the EORTC QLQ-C30 PF scores, again indicating the impact of the loss of a (part of a) limb. In addition, involvement of the lower extremities resulted in non-statistical lower functionality compared to the upper extremity, especially in the IR-A group, but the numbers of the subgroups were low. The results in the IR-A group were on some scales worse than the A group, however, these differences were not statistically significant. The fact that a high percentage of survivors in the ER group had additional radiotherapy could potentially negatively affect scores on the EORTC QLQ C30 PF scale and TESS for this group due to late radiotherapy side effects. However, this is not reflected in our results since there were no statistical significant differences between patients receiving radiotherapy or not receiving radiotherapy in the different groups.

It is notable that the EORTC QLQ-C30 PF and RF are the only two scales with statistical lower scores without affecting the other scales, such as social functioning, and it raises the question whether the EORTC QLQ-C30 questionnaire, which has never been validated for amputees, is applicable to survivors with an amputation. However, physical discomfort does not always translate into a decrease in other domains of HRQoL.

Although there is no difference in distance metastases between the different surgical approaches [3,18,19], the risk of local recurrence is lower in case of an amputation. However, no difference in fear of cancer recurrence in favor of the amputation group was observed in our study. Also, no differences were found in anxiety or depression between the different eSTS survivor groups. Shared decision making with the patient on either IR, ER or A may be an explanation for this observation.

Despite the fact that we expected a cosmetic benefit from limb-sparing surgery, survivors with an amputation were more satisfied with their scar. The most plausible explanation is that the impact of an amputation is already much more profound compared to a limb sparing resection, which makes the appearance of the scar




Fig. 2. Statistical significant differences: EORTC QLQ-C30 and TESS.

Table 3  
Questionnaires CWS, HADS and TESS.

Questionnaire	Limb salvage surgery						Amputation						p
	ILP + resection (IR) (n = 20)			Extended resection (ER) (n = 49)			Amputation (A) (n = 20)			ILP + amputation (IR-A) (n = 8)			
	Mean	SD	n (%)	Mean	SD	n (%)	Mean	SD	n (%)	Mean	SD	n (%)	
Cancer worry scale (CWS)	14.5	6.4	20	13.5	4.0	49	14.1	4.9	19	13.0	3.6	7	0.828
Low (≤13)			12 (60)			29 (59)			10 (53)			4 (57)	0.962
High (>14)			8 (40)			20 (41)			9 (47)			3 (43)	
Hospital Anxiety and Depression Scale (HADS)													
Anxiety	3.8	3.8	20	3.7	3.6	49	4.5	3.5	19	4.1	2.3	7	0.851
Low (≤7)			17 (85)			37 (76)			15 (79)			7 (100)	0.500
High (>8)			3 (15)			11 (22)			4 (21)			0 (0)	
Depression	4.1	3.6	20	3.6	3.4	49	5.2	4.3	19	4.0	3.2	7	0.494
Low (≤7)			16 (80)			43 (88)			13 (68)			6 (86)	0.213
High (>8)			4 (20)			5 (10)			6 (32)			1 (14)	
Toronto Extremity Salvage Score (TESS)													
Upper extremity	93.3	7.3	3 (15)	91.1	11.2	8 (16)	68.9	17.1	6 (30)	71.6	5.4	4 (50)	0.007 <sup>a</sup>
Lower extremity	84.5	13.4	16 (80)	85.5	13.1	36 (73)	72.2	21.2	14 (70)	50.9	23.9	4 (50)	<0.001 <sup>a</sup>

<sup>a</sup> Post Hoc test showed for TESS upper extremity a significant difference of p = 0.022 between amputation and the extended resection group. For the TESS lower extremity showed a significant difference of p = 0.002 between the ILP group and the ILP + amputation group and a p = 0.001 between the ILP + amputation group and the extended resection group.

itself irrelevant. Our questionnaire unfortunately did not address body image, which was negatively affected in previous research by post-treatment effects and caused a decrease in HRQoL [39].

Our study has several novel findings: first, we present the results of a population-based survivorship study with participation of 6 sarcoma centers and validated questionnaires. Compared to other studies which were mostly monocenter, our study also has the largest group of survivors with one of the longest follow-up periods and is the first to compare all different local treatment options for locally advanced eSTS.

However, our study has several limitations. First of all, the number of included survivors who underwent certain special treatments is relatively low (especially the IR-A is small, n = 8), which reflects the high percentage of successful ILP's and is consistent with what we see in daily practice. Secondly, all data regarding tumor characteristics or treatment are either based on PRO's or the national registry and therefore several details are not available. Unfortunately, data is also missing regarding disease

status at the time of the study and treatments undertaken for any recurrent or metastatic disease, which could affect the HRQoL. A third limitation is that there might be an underrepresentation of stage III tumors in this study, which could be explained by a potential survivorship bias given the relatively poor prognosis of stage III patients. Fourth, there is a (non-) respondent bias, since only 58% of all NCR registered survivors with eSTS in the participating centers did complete their questionnaire. The last limitation is that the symptoms and limitations survivors experience in their daily life may not always be due to the diagnosis (2–10 years ago) or treatment of their eSTS (recall bias) and the fact that patient reported data is not always reliable in their specificity when it comes to objective clinical data. In addition, it is important to acknowledge that ILP is relatively widely available in the Netherlands with 3 centers that provide this treatment, on a total population of around 17 million.

An improvement in future HRQoL research could be longitudinal studies with multiple measurements, which bypasses a possible

**Table 4**  
Late effects of surgery.

Question	Limb salvage surgery				Amputation				p
	ILP + resection (IR) (n = 20)		Extended resection (ER) (n = 49)		Amputation (A) (n = 20)		ILP + amputation (IR-A) (n = 8)		
	n	(%)	n	(%)	n	(%)	n	(%)	
Scar left from surgery	20	(100)	48	(98)	20	(100)	7	(88)	0.161
Ugly scar left from surgery <sup>a</sup>	11	(55)	27	(55)	6	(30)	1	(12)	0.001
Inconvenience of the scar <sup>b</sup>									
Visible for other people	3	(15)	6	(12)	2	(10)	0	–	0.779
Usage of pain medication	1	(5)	3	(6)	0	–	1	(12)	0.433
Changed skin sensitivity	11	(55)	19	(38)	6	(30)	1	(13)	0.253
Wound issues	2	(10)	3	(6)	1	(4)	2	(25)	0.234
Post amputation pain (PAP)									0.717
Arm	–	–	–	–	4	(57) <sup>c</sup>	1	(25) <sup>c</sup>	
Leg	–	–	–	–	7	(50) <sup>c</sup>	4	(100) <sup>c</sup>	

<sup>a</sup> Question with multiple answer possibilities (yes, no, no opinion). Only respondents who answers 'yes' are shown.

<sup>b</sup> Question with multiple answer possibilities. Other options were 'no burden' or 'yes [own answer]'.

<sup>c</sup> Percentages are based on total amputations per subgroup.

recall bias and could give even more information on the course of HRQoL over time. As reported by van Eck et al., a more specified HRQoL measurement is needed to capture more disease and treatment specific HRQoL, for example the EORTC QLQ C-30 supplemented with items from the EORTC Item Library, which is currently being investigated [40].

Despite all the limitations, this study illustrates that ILP can prevent a significant decrease in HRQoL, which would favor a more liberal use of ILP for patients otherwise needing an amputation. This does depend, however, on the availability of ILP per country.

## 5. Conclusion

In conclusion, ILP followed by resection has comparable long-term HRQoL results compared to extended resection and has superior functional patient reported outcome compared to patients undergoing an amputation. These results confirm and justify that ILP should be considered as induction therapy in order to prevent amputation, since this can prevent a decrease in HRQoL for patients with locally advanced eSTS. However, a secondary amputation after ILP seem to result in worse HRQoL compared to patients undergoing a primary amputation, emphasizing the need to better select patients and histological subtypes potentially benefitting from an ILP and identifying risk factors for severe complications.

## CRedit authorship contribution statement

**Sophie J.M. Reijers:** Conceptualization, Formal analysis, Validation, Investigation, Data curation, Writing – original draft, Visualization. **Olga Husson:** Conceptualization, Methodology, Validation, Formal analysis, Writing – review & editing, Visualization, Supervision, Project administration. **Vicky L.M.N. Soomers:** Conceptualization, Resources, Data curation, Writing – review & editing. **Lukas B. Been:** Conceptualization, Resources, Writing – review & editing. **Johannes J. Bonenkamp:** Conceptualization, Resources, Writing – review & editing. **Michiel A.J. van de Sande:** Conceptualization, Resources, Writing – review & editing. **Cornelis Verhoef:** Conceptualization, Resources, Writing – review & editing. **Winette T.A. van der Graaf:** Conceptualization, Methodology, Resources, Writing – review & editing, Visualization, Supervision. **Winan J. van Houdt:** Conceptualization, Methodology, Resources, Writing – original draft, Visualization, Supervision, Project administration.

## Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## References

- [1] Roland CL, et al. ASO author reflections: moving the needle in extremity and trunk soft tissue sarcoma. *Ann Surg Oncol* 2020.
- [2] Ghert MA, et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. *Ann Surg Oncol* 2005;12:10–7.
- [3] Williard WC, et al. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. *Ann Surg* 1992;215:269–75.
- [4] Noorda EM, et al. Isolated limb perfusion: what is the evidence for its use? *Ann Surg Oncol* 2004;11:837–45.
- [5] Assi T, et al. Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience. *Clin Transl Oncol* 2019;21:1135–41.
- [6] Jakob J, et al. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection. *J Surg Oncol* 2014;109:786–90.
- [7] Deroose JP, et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. *J Clin Oncol* 2011;29:4036–44.
- [8] Benckhuijsen C, et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. *Eur J Surg Oncol* 1988;14:157–63.
- [9] Grunhagen DJ, et al. Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. *Ann Surg Oncol* 2005;12:473–9.
- [10] Neuwirth MG, et al. Isolated limb perfusion and infusion for extremity soft tissue sarcoma: a contemporary systematic review and meta-analysis. *Ann Surg Oncol* 2017;24:3803–10.
- [11] Trabulsi NH, et al. Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials. *J Surg Oncol* 2012;106:921–8.
- [12] Smith HG, et al. Isolated limb perfusion with melphalan and tumour necrosis factor alpha for in-transit melanoma and soft tissue sarcoma. *Ann Surg Oncol* 2015;22(Suppl 3):S356–61.
- [13] Jakob J, Hohenberger P. Role of isolated limb perfusion with recombinant human tumor necrosis factor alpha and melphalan in locally advanced extremity soft tissue sarcoma. *Cancer* 2016;122:2624–32.
- [14] Rastrelli M, et al. Isolated limb perfusion for the management limb threatening soft tissue sarcomas: the role of histological type on clinical outcomes. *Eur J Surg Oncol* 2017;43:401–6.
- [15] Huis In 't Veld EA, et al. Isolated limb perfusion for locally advanced angio-sarcoma in extremities: a multi-centre study. *Eur J Canc* 2017;85:114–21.
- [16] Olofsson R, et al. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity. *Ann Surg Oncol* 2012;19:1800–7.
- [17] Wieberdink J, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. *Eur J Cancer Clin Oncol* 1982;18:905–10.
- [18] Alamanda VK, et al. Amputation for extremity soft tissue sarcoma does not increase overall survival: a retrospective cohort study. *Eur J Surg Oncol* 2012;38:1178–83.



- [19] Rosenberg SA, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. *Ann Surg* 1982;196:305–15.
- [20] Soomers V, et al. Patient and diagnostic intervals of survivors of sarcoma: results from the SURVSARC study. *Cancer* 2020;126:5283–92.
- [21] WCoTE Board. Soft tissue and bone tumours. fifth ed. Lyon (France): International Agency for Research on Cancer; 2020.
- [22] Aaronson NK, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85:365–76.
- [23] Fayers Nka P, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual. third ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
- [24] Custers JA, et al. The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors. *Cancer Nurs* 2014;37:E44–50.
- [25] Douma KF, et al. Psychological distress and use of psychosocial support in familial adenomatous polyposis. *Psycho Oncol* 2010;19:289–98.
- [26] Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361–70.
- [27] Davis AM, et al. Development of a measure of physical function for patients with bone and soft tissue sarcoma. *Qual Life Res* 1996;5:508–16.
- [28] Cocks K, et al. Evidence-based guidelines for determination of sample size and interpretation of the European organisation for the research and treatment of cancer quality of life questionnaire core 30. *J Clin Oncol* 2011;29:89–96.
- [29] Thijssens KM, et al. Quality of life after hyperthermic isolated limb perfusion for locally advanced extremity soft tissue sarcoma. *Ann Surg Oncol* 2006;13:864–71.
- [30] Podleska LE, et al. Lower limb function and quality of life after ILP for soft-tissue sarcoma. *World J Surg Oncol* 2017;15:84.
- [31] Zahlten-Hinguranage A, et al. Equal quality of life after limb-sparing or ablative surgery for lower extremity sarcomas. *Br J Canc* 2004;91:1012–4.
- [32] Sugarbaker PH, et al. Quality of life assessment of patients in extremity sarcoma clinical trials. *Surgery* 1982;91:17–23.
- [33] Saebye C, et al. Changes in functional outcome and quality of life in soft tissue sarcoma patients within the first year after surgery: a prospective observational study. *Cancers (Basel)* 2020;12.
- [34] Schreiber D, et al. Evaluating function and health related quality of life in patients treated for extremity soft tissue sarcoma. *Qual Life Res* 2006;15:1439–46.
- [35] Davidge K, et al. Patient expectations for surgical outcome in extremity soft tissue sarcoma. *J Surg Oncol* 2009;100:375–81.
- [36] Johansen R, et al. Functional outcome in sarcomas treated with limb-salvage surgery or amputation. *Sarcoma* 1998;2:19–23.
- [37] Davis AM, et al. Functional outcome in amputation versus limb sparing of patients with lower extremity sarcoma: a matched case-control study. *Arch Phys Med Rehabil* 1999;80:615–8.
- [38] Furtado S, et al. Physical functioning, pain and quality of life after amputation for musculoskeletal tumours: a national survey. *Bone Joint Lett J* 2015;97-B:1284–90.
- [39] Taylor MF, Pooley JA. Sarcoma survivors' perspectives on their body image and functional quality of life post-resection/limb salvage surgery. *Eur J Canc* 2017;26.
- [40] van Eck I, et al. Unraveling the heterogeneity of sarcoma survivors' health-related quality of life regarding primary sarcoma location: results from the SURVSARC study. *Cancers (Basel)* 2020;12.